WO2025247364 - HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/247364
Publication Date
04.12.2025
International Application No.
PCT/CN2025/098289
International Filing Date
30.05.2025
Title **
[English]
HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF
[French]
COMPOSÉ HÉTÉROCYCLIQUE UTILISÉ EN TANT QU'INHIBITEUR DE CDK ET SON UTILISATION
[Chinese]
杂环化合物作为CDK抑制剂及其用途
Applicants **
SHANDONG SIMCERE BIOPHARMACEUTICAL CO., LTD.
Inventors
JIN, Jinghai
ZHU, Wei
BAI, Gang
JIANG, Lei
YANG, Shuqun
LI, Zhengtao
Priority Data
202410690167.9
30.05.2024
CN
202410923712.4
10.07.2024
CN
202411380899.4
30.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2712 | |
| EPO | Filing, Examination, Granting | 24640 | |
| Japan | Filing, Examination, Granting | 2930 | |
| South Korea | Filing, Examination, Granting | 3728 | |
| USA | Filing, Examination, Granting | 8540 |
Total:
42,550
Contact Us
Abstract[English]
The present disclosure relates to a CDK4 inhibitor compound represented by formula (Z) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and use thereof in the preparation of a medicament for preventing or treating a CDK4-mediated disease.[French]
La présente invention concerne un composé inhibiteur de CDK4 représenté par la formule (Z) ou un sel pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique le comprenant, et son utilisation dans la préparation d'un médicament pour la prévention ou le traitement d'une maladie médiée par CDK4.[Chinese]
本公开涉及式（Z）所示CDK4抑制剂化合物或其药学上可接受的盐、含有它们的药物组合物、以及其在制备预防或治疗CDK4介导的疾病的药物中的用途。